Stimuli‐responsive “smart” hydrogel biomaterials have attracted great attention in the
biomedical field, especially in designing novel on‐demand drug delivery systems. As a …

Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …

Arrhythmogenic cardiomyopathy (ACM) is an inherited progressive cardiac disease. Many
patients with ACM harbor mutations in desmosomal genes, predominantly in plakophilin-2 …

With the continuous improvement in survival of cancer patients, including those with multiple
myeloma, related to the novel treatment agents and therapeutic approaches, the probability …

Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has
undergone remarkable changes over the past 25 years. Small molecules (molecular weight …

Multiple myeloma (MM) is a malignant clonal plasma cell disorder in the bone marrow and is
the second-most common hematologic malignancy in adults. Although patients with MM …

Maintenance of protein homeostasis is crucial for virtually every aspect of eukaryotic biology.
The ubiquitin-proteasome system (UPS) represents a highly regulated quality control …

In this overview we present a summary of evidence from systematic reviews (SRs) on the
safety and efficacy of carfilzomib in multiple myeloma (MM). Our search in electronic …

The present study is an overview of systematic reviews focusing on adverse events of
antimyeloma treatments. It provides a systematic description of adverse events as they are …

In recent years, advancements in the treatment of hematologic neoplasms have led to more
effective and less toxic therapeutic schemes, resulting in prolonged patient life expectancy …